Read more about J&J seeks approval for single-dose Covid-19 vaccine in India on Business Standard. It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers
Reuters
Published: 23 Apr 2021 05:29 PM BdST
Updated: 23 Apr 2021 05:29 PM BdST Johnson & Johnson s coronavirus disease (COVID-19) vaccines are kept refrigerated at the Forem vaccination centre in Pamplona, Spain, Apr 22, 2021. REUTERS
Johnson & Johnson s single-shot COVID-19 vaccine is expected to be imported to India for fill and finish by June or July, financial daily Mint reported on Friday, citing ANI. );
}
Fill and finish is the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping.
India has said it would fast-track emergency approvals for COVID-19 vaccines authorised by Western countries and Japan, paving the way for possible imports of Pfizer, Johnson & Johnson and Moderna shots.
WHO grants EUL to J&Jâs single-shot COVID-19 vaccine
WHO grants EUL to J&Jâs single-shot COVID-19 vaccine 15 March 2021 | News The data also demonstrated the vaccine was 85 per cent effective in preventing severe disease across all regions studied
Source credit: Shutterstock
Johnson & Johnson has announced that the World Health Organization (WHO) has issued emergency use listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 per cent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants given the placebo. The onset of protection was observed from day 14 and was maintained 28 days post-vaccination.
The Atlantic
Yes, all of the COVID-19 vaccines are very good. No, they’re not all the same.
Adam Maida / Getty / The Atlantic
Public-health officials are enthusiastic about the new, single-shot COVID-19 vaccine from Johnson & Johnson, despite its having a somewhat lower efficacy at preventing symptomatic illness than other available options. Although clinical-trial data peg that rate at 72 percent in the United States, compared with 94 and 95 percent for the Moderna and Pfizer-BioNTech vaccines, many experts say we shouldn’t fixate on those numbers. Much more germane, they say, is the fact that the Johnson & Johnson shot, like the other two, is essentially perfect when it comes to preventing the gravest outcomes. “I’m super-pumped about this,” Virginia’s vaccine coordinator told
Health officials said Virginia will begin dispensing Johnson & Johnson's COVID-19 vaccine next week following the FDA's emergency use authorization Saturday of the one-shot inoculation.